AstraZeneca announced on Monday that a phase 2 clinical trial of Tezspire, its new asthma treatment, failed to meet its primary endpoint in chronic obstructive pulmonary disease (COPD).

Initial results from the trial show that the drug, administered by injection, reduced exacerbations of COPD-related symptoms by only 17% over a full year, a level deemed statistically insignificant.

The laboratory does, however, highlight data deemed 'encouraging' in patients with a blood eosinophil count greater than or equal to 150 cells/µL, a sub-category which accounts for 65% of COPD patients.

In this patient population, the reduction in moderate or severe exacerbations reached 37%, a result that can be considered significant this time.

Tezspire, developed in collaboration with Amgen, is a human monoclonal antibody that inhibits a key cytokine responsible for the persistence of allergic-type respiratory inflammation.

Copyright (c) 2024 CercleFinance.com. All rights reserved.